AKT1 and cancer: The compound exhibits a broad spectrum of anti-cancer activities by inducing the degradation of client proteins involved in key pathways such as Mitogen-Activated Protein Kinase (MAPK), Phosphoinositide 3-Kinase (PI3K)/protein kinase B (Akt), and Janus kinase (JAK)/signal transducers and activators of transcription (STAT) (Figure 3).